Plasma Supply Falling Behind Demand: Kristopher Jonas Sounds the Alarm
Kristopher Jonas, CEO/President of Proesis Biologics, posted on LinkedIn:
”You know what’s scary?
The growing gap between how much plasma-derived medicine the world needs and how much plasma we’re actually collecting.
Global demand for immunoglobulins (IG) continues to climb 6–8% each year. And that’s not even factoring in underutilization in low to middle-income countries.
Fractionators are bringing new manufacturing capacity online across the U.S. and Europe.
But all that capacity still depends on one thing – human plasma – and the supply side isn’t keeping pace.
That’s where independent collectors come in.
We’re the flexible link in the chain, able to expand quickly, reach new donor communities, and help ensure the growing global infrastructure doesn’t sit idle waiting for plasma.
Not spooky. Just real.
And it’s why what we’re building at Proesis Bio matters.”
Keep up with Hemostasis Today.
-
Jul 13, 2026, 15:15Alfonso J. Tafur: Insights on Periprocedural DOAC Management in Atrial Fibrillation at
-
Jul 13, 2026, 14:42Bruno Pougault: The Global Momentum Behind Innovation in Thrombosis and Hemostasis
-
Jul 13, 2026, 14:34Julie Vassart: Optimizing DOAC Detection in an Evolving Anticoagulant Landscape at ISTH 2026
-
Jul 13, 2026, 13:57Heghine Khachatryan: The Diagnostic Dilemma of Non-Criteria Obstetric APS
-
Jul 13, 2026, 13:49Mitra Najafi: Translating Years of Innovation into Global Scientific Dialogue at ISTH 2026
-
Jul 13, 2026, 13:2810 Posts Not To Miss from ISTH 2026, Part 2
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:49Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
-
Jul 13, 2026, 10:25Flora Peyvandi: A Practical Approach to ALT Elevation After Gene Therapy at ISTH 2026